MX2021003496A - Potenciacion del tratamiento contra helmintos. - Google Patents

Potenciacion del tratamiento contra helmintos.

Info

Publication number
MX2021003496A
MX2021003496A MX2021003496A MX2021003496A MX2021003496A MX 2021003496 A MX2021003496 A MX 2021003496A MX 2021003496 A MX2021003496 A MX 2021003496A MX 2021003496 A MX2021003496 A MX 2021003496A MX 2021003496 A MX2021003496 A MX 2021003496A
Authority
MX
Mexico
Prior art keywords
potentiation
treatment
helminth
effective amount
helminth treatment
Prior art date
Application number
MX2021003496A
Other languages
English (en)
Inventor
Sarah George
Peter Rolfe
Chouaib Tahtaoui
Original Assignee
Elanco Tiergesundheit Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco Tiergesundheit Ag filed Critical Elanco Tiergesundheit Ag
Publication of MX2021003496A publication Critical patent/MX2021003496A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona un método para tratar infecciones por trematodos hepáticos en un mamífero que necesita dicho tratamiento, que comprende administrar una cantidad eficaz de diafenetida en combinación con una cantidad eficaz de clorsulon.
MX2021003496A 2018-10-04 2019-09-30 Potenciacion del tratamiento contra helmintos. MX2021003496A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862741120P 2018-10-04 2018-10-04
PCT/US2019/053750 WO2020072343A1 (en) 2018-10-04 2019-09-30 Potentiation of helminth treatment

Publications (1)

Publication Number Publication Date
MX2021003496A true MX2021003496A (es) 2021-06-23

Family

ID=68242870

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003496A MX2021003496A (es) 2018-10-04 2019-09-30 Potenciacion del tratamiento contra helmintos.

Country Status (12)

Country Link
US (2) US11938103B2 (es)
EP (1) EP3860583A1 (es)
JP (1) JP7211683B2 (es)
CN (1) CN113194937A (es)
AR (1) AR116524A1 (es)
AU (1) AU2019355831B2 (es)
BR (1) BR112021005666A2 (es)
CA (1) CA3113830A1 (es)
MX (1) MX2021003496A (es)
RU (1) RU2766763C1 (es)
WO (1) WO2020072343A1 (es)
ZA (1) ZA202102023B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR116524A1 (es) * 2018-10-04 2021-05-19 Elanco Tiergesundheit Ag Potenciación de tratamiento de helmintos

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896235A (en) 1970-09-01 1975-07-22 Burroughs Wellcome Co Anthelmintic ethers and composition thereof
US4064239A (en) 1974-12-16 1977-12-20 Merck & Co., Inc. Halogenated unsaturated alkyl benzenedisulfonamides as anthelmintics
FR2361109A1 (fr) * 1976-08-13 1978-03-10 Wellcome Found Medicaments anthelminthiques
SU697500A1 (ru) * 1977-02-14 1979-11-15 Ордена Трудового Красного Знамени Институт Медицинской Паразитологии И Тропической Медицины Им. Е.И.Марциновского Салициланилиды, обладающие антигельминтной активностью
EP0710105B1 (en) * 1993-06-15 2003-07-30 The Australian National University Synergistic anthelmintic compositions against fasciola hepatica and other fasciola species
EP1129713A1 (en) * 2000-02-29 2001-09-05 New Pharma Research Sweden AB Veterinary compositions for the treatment of parasitic diseases
AU2003249244A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
GB0501220D0 (en) * 2005-01-21 2005-03-02 Norbrook Lab Ltd Anthelmintic composition
PT2170321E (pt) * 2007-06-29 2013-08-01 Zoetis Llc Combinação anti-helmíntica
AU2008329706B2 (en) * 2007-11-26 2013-01-10 Boehringer Ingelheim Animal Health USA Inc. Solvent systems for pour-on formulations for combating parasites
ME03323B (me) * 2012-02-06 2019-10-20 Merial Inc Paraziticidne oralne veterinarske kompozicije koje sadrže sistemski djelujuća aktivna sredstva, metodi i primjene istih
CA3186350A1 (en) * 2013-02-27 2014-09-04 Argenta Innovation Limited Transdermal formulations
WO2014141223A1 (en) * 2013-03-15 2014-09-18 Argenta Manufacturing Limited Chewable formulation
UY36196A (es) * 2014-07-25 2016-02-29 Bayer Animal Health Gmbh Compuestos para usar en el tratamiento antihelmíntico
AR101743A1 (es) * 2014-09-12 2017-01-11 Bayer Cropscience Ag Derivados de arilsulfuro y arilsulfóxido con uracilos unidos por c-c como agentes de control de plagas
AU2015340755A1 (en) * 2014-10-28 2017-04-27 Bayer Animal Health Gmbh Compounds for use in anthelminthic treatment
CN107257793A (zh) * 2015-01-20 2017-10-17 梅里亚股份有限公司 抗蠕虫化合物、组合物及其使用方法
ES2851345T3 (es) * 2015-04-02 2021-09-06 Boehringer Ingelheim Animal Health Usa Inc Combinaciones antihelmínticas y procedimientos de utilización de las mismas
JP6824900B2 (ja) * 2015-04-08 2021-02-03 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド イソオキサゾリン活性薬剤を含む延長放出注射製剤、方法及びその使用
AU2016317848A1 (en) * 2015-09-03 2018-03-15 Agrimetis, Llc Spinosyn derivatives as insecticides
CN107868024A (zh) * 2017-10-25 2018-04-03 浙江海正药业股份有限公司 克洛索隆的晶型及其制备方法和用途
AR116524A1 (es) * 2018-10-04 2021-05-19 Elanco Tiergesundheit Ag Potenciación de tratamiento de helmintos

Also Published As

Publication number Publication date
AU2019355831B2 (en) 2022-10-06
CA3113830A1 (en) 2020-04-09
WO2020072343A1 (en) 2020-04-09
US20220008366A1 (en) 2022-01-13
RU2766763C1 (ru) 2022-03-15
AU2019355831A1 (en) 2021-04-22
US11938103B2 (en) 2024-03-26
BR112021005666A2 (pt) 2021-06-22
CN113194937A (zh) 2021-07-30
EP3860583A1 (en) 2021-08-11
JP7211683B2 (ja) 2023-01-24
ZA202102023B (en) 2023-09-27
US20240173275A1 (en) 2024-05-30
AR116524A1 (es) 2021-05-19
JP2022502394A (ja) 2022-01-11

Similar Documents

Publication Publication Date Title
CY1123678T1 (el) Χρηση αναστολεων μυοστατινης και θεραπειες συνδυασμου
CO2021000151A2 (es) Inhibidores de pd-1/pd-l1
EA201890161A1 (ru) Терапевтические композиции, комбинации и способы применения
CL2020002018A1 (es) Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582)
MX2024000348A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
BR112018009311A2 (pt) ?método para tratar um sujeito humano sofrendo de tma persistente associada com transplante de célula tronco hematopoiética?
EA201792496A1 (ru) Способы лечения воспаления или нейропатической боли
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
ECSP20082339A (es) Moduladores de la expresión de apol1
DOP2021000130A (es) Moduladores de la expresion de hsd17b13
EA201992170A1 (ru) Модуляторы экспрессии pcsk9
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
CO2021007006A2 (es) Moduladores de la expresión de irf5
CO2022000214A2 (es) Composiciones para el tratamiento de la pérdida del cabello
ZA202102023B (en) Potentiation of helminth treatment
PH12019502578A1 (en) Methods of treatment for cervical dystonia
MX2020003554A (es) Moduladores de la expresion de enac.
MX2022007453A (es) Potenciacion de tratamiento contra helmintos.
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
CO2021014747A2 (es) Métodos para el tratamiento de βeta-talasemia
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.
EA202192037A1 (ru) Способ лечения боли при остеоартрите путем введения резинифератоксина